New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
09:16 EDTHTZ, BTU, HDSN, SEAC, CMTL, NVAX, RALY, GWPH, ANGI, DMNDOn The Fly: Pre-market Movers
HIGHER: Angie's List (ANGI), up 7% after shares upgraded at BofA Merrill Lynch... GW Pharmaceuticals (GWPH), up 7.5% after receiving Fast Track designation for Epidiolex... Comtech (CMTL), up 6% after Q3 earnings beat, raised FY14 outlook. LOWER: Hertz (HTZ), down 10% after warning its Q1 results are "likely to be below consensus," disclosing that errors were identified during its preparation of its financial statements and that certain statements must be restated... Rally Software (RALY), down 23% after downgraded at William Blair, Deutsche Bank and Needham following the company's Q1 results... Novavax (NVAX), down 7.5% after filing to sell $100M of common stock... SeaChange (SEAC), down 10% after reporting disappointing earnings, guidance... Diamond Foods (DMND), down 7.5% after reporting lower than expected Q3 results... Hudson Technologies (HDSN), down 6.5% after 6M share spot secondary offering of shares priced at $2.50... Peabody (BTU), down 2% after shares downgraded at Goldman.
News For HTZ;ANGI;GWPH;RALY;NVAX;CMTL;SEAC;HDSN;BTU;DMND From The Last 14 Days
Check below for free stories on HTZ;ANGI;GWPH;RALY;NVAX;CMTL;SEAC;HDSN;BTU;DMND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 23, 2014
08:47 EDTNVAXNovavax announces BARDA exercise of contract option
Subscribe for More Information
08:41 EDTNVAXNovavax H7N9 vaccine candidate delivers positive Phase 1/2 clinical data
Novavax announced positive top-line data from a Phase 1/2 clinical trial of its H7N9 Avian Influenza VLP Vaccine Candidate, or H7N9 VLP, with proprietary adjuvant Matrix-M. This trial was conducted under the company's contract with HHS-BARDA for the development of VLPs to address influenza strains with pandemic potential. The H7N9 VLP, with and without Matrix-M, was well tolerated and demonstrated a safety profile similar to the company's prior experience with another saponin-based adjuvant. Matrix-M adjuvanted formulations demonstrated a clear immunogenicity benefit relative to unadjuvanted antigen, and a dose-response within the adjuvanted groups. Antigen dose-sparing was shown, such that even the 3.75g dose of antigen with either tested dose of adjuvant gave immune responses statistically significantly greater than 15g dose without adjuvant. Geometric mean titers of hemagglutination-inhibiting antibody after two vaccine doses were comparable to those reported in prior studies with another saponin adjuvant when similar antigen and adjuvant doses were compared. The vaccine also elicited anti-neuraminidase antibodies against N9, with 89 to 100% sero-response rates in the adjuvanted vaccine groups, and greater than 11-fold increases in geometric mean titers.
September 22, 2014
14:32 EDTCMTLComtech announces $6.1M increase in order funding
Subscribe for More Information
07:51 EDTGWPHGW Pharmaceuticals could trade up 25% on data, says Leerink
Leerink believes shares of GW Pharmaceuticals could trade up 25% should the Epidiolex data in pediatric epilepsy show a seizure reduction materially greater than 44%. The data is expected in the second half of 2014. The firm says shares could trade up 15% higher on a reduction at or close to 40%, or 15% lower if the mean reduction is in the 20%-30% range. Leerink is bullish ahead of the data readout after reviewing the cannabidiol epilepsy literature and previous anti-epileptic drug trials. It has an Outperform rating on shares of GW Pharmaceuticals with a $110 price target.
September 19, 2014
08:05 EDTHTZHertz says China partner IPOs in Hong Kong
Subscribe for More Information
07:41 EDTNVAXNovavax coverage assumed with an Outperform at Wedbush
Subscribe for More Information
September 18, 2014
15:52 EDTANGIAngie's List upside potential outweighs downside risk, says Barrington
After meetings with management, Barrington said Angie's List is taking the right steps in improving its website and mobile apps. The firm believes there is "much more" upside potential than downside risk in the stock and maintains its Outperform rating and $15 price target on the shares.
14:46 EDTBTUPeabody sees Q3 Powder River Basin shipments above Q2 levels
Subscribe for More Information
14:45 EDTBTUPeabody says India thermal coal imports rising faster than expected
Subscribe for More Information
14:43 EDTBTUPeabody sees new China coal quality policies to have no negative impact
Subscribe for More Information
14:21 EDTBTUPeabody Energy volatility flat as shares trend to ten-year low
Peabody Energy September weekly call option implied volatility is at 31, October is at 33, December is at 31; compared to its 26-week average of 32 according to Track Data, suggesting non-directional price movement.
11:16 EDTNVAXNovavax to host analyst and investor day
Subscribe for More Information
10:00 EDTBTUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:32 EDTANGIMKM Partners to hold a conference
Subscribe for More Information
06:08 EDTBTUPeabody downgraded to Sell from Neutral at Goldman
Goldman downgraded Peabody to Sell based on a reduced met coal price forecast, valuation, low Australia margins, and high leverage levels. Price target lowered to $13 from $15.
September 16, 2014
16:09 EDTNVAXNovavax initiates Phase 2 trial of RSV F vaccine candidate
Subscribe for More Information
09:59 EDTBTUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:25 EDTBTUOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTHTZHertz and Carl Icahn reach agreement regarding board appointments
Subscribe for More Information
07:16 EDTBTUPeabody downgraded to Reduce from Neutral at Nomura
Nomura downgraded Peabody to Reduce based on reduced coking and thermal coal price forecasts and reduced its price target to $11.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use